Track topics on Twitter Track topics that are important to you
Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 Growth Driven by Rising Awareness and Expected Launch of Novel Therapies
Atopic dermatitis AD, also called atopic eczema, is a chronic, pruritic, inflammatory skin disease arising from a complex interrelationship of environmental, immunologic, genetic, and pharmacologic factors, with a characteristic phenotype and typically distributed skin lesions.
It is one of the most common skin diseases, affecting approximately 20% of children and 13% of adults globally. AD is a genetically complex, familial transmitted disease with a strong maternal influence; a child possesses a twofold risk of developing the disease if one of the parents is affected and a threefold risk if both are affected. Many studies reported that increasing urbanization, westernization of lifestyle, obesity, lack of physical exercise, stress, food allergies, and pollution increase the risk of AD.
The current marketed drug landscape in AD includes topical agents corticosteroids and calcineurin inhibitors, systemic therapies such as corticosteroids, cyclosporine, azathioprine, methotrexate and mycophenolatemofetil and a biologic therapy Dupixent. Topical steroids have been the mainstay of treatment for AD in both children and adults for the past half century.
The evolution in the understanding of the pathogenesis of AD has led to the discovery and development of several promising treatment options for AD. Recently, two new therapies have been approved for AD, Eucrisa crisaborole and Dupixent dupilumab. However, currently Sanofi/Regeneron'sDupixent is the only targeted therapy that is available in Southeast Asia AD market.
The latestage AD pipeline contains promising therapies that have the potential to achieve approval and launch over the forecast period. These include LEO Pharma'stralokinumab, Eli Lilly's baricitinib, Kangstem Biotech's furestemAD, Pfizer's PF04965842 and Amorepacific's PAC14028. These new drugs will expand the options available to treat AD patients and contribute to overall market growth by offering novel treatment mechanisms.
The Southeast Asia AD market will be valued at $848.6m in 2024, growing from $423.2m in2017, at a compound annual growth rate of 10.5%.
What are the key factors driving the Southeast Asia AD treatment market?
What classes of drugs dominate the market?
How will the market respond to recent approval?
How will novel IL4Ra inhibitor therapy Dupixent, which holds firsttomarket advantage, contribute to growth?
The AD pipeline contains a range of molecule types and molecular targets, including those that are well established in AD and novel target therapies.
Which classes of novel drugs are most prominent in the pipeline?
What are the common targets and mechanisms of action of pipeline therapies?
Latestage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
How have the latestage therapies performed in clinical trials?
What are the commercial prospects for the most promising latestage products?
How will the approval of tralokinumab, furestemAD, baricitinib, PAC14028 and PF04965842, affect the competitive landscape?
Various drivers and barriers will influence the market over the forecast period.
Which factors are most likely to drive the market in these countries?
What licensing and codevelopment deals have occurred within this therapy area since 2007?
Reasons to buy
This report will enable you to:
Understand the current clinical and commercial landscape of AD by considering epidemiology, symptoms, etiology and pathophysiology, diagnosis, prognosis and treatment guidelines and options.
Visualize the composition of the AD market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.
Identify key pipeline trends in terms of molecule type, administration route, molecular target, and novelty.
Consider market opportunities and potential risks by examining trends in AD clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target.
Understand the potential of latestage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
Predict AD market growth in the eight assessed Southeast Asian markets, with epidemiological and annual cost of therapy forecasts across South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia, as well as the individual contributions of promising latestage molecules to market growth.
Discover trends in licensing and codevelopment deals concerning AD products and identify the major strategic consolidations that have shaped the commercial landscape.
Original Article: Atopic Dermatitis Therapeutics in Southeast Asia Markets to 2024 Growth Driven by Rising Awareness and Expected Launch of Novel Therapies [Report Updated: 15112018] Prices from USD $4396NEXT ARTICLE
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...
Dermatitis means an inflammation of the skin. Contact dermatitis is a term used when this inflammation is caused by contact with something in the environment. The changes of dermatitis seen in the skin take the form of eczema; hence it may sometimes be r...
Anything that breaks the skin is a wound because when the skin is broken, there's a risk of germs getting into the body and causing an infection. Follow and track Wound Care News on BioPortfolio: Wound Car...